Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Randomized Disrupt PAD III Study Finds Superior Vessel Preparation Leads to Excellent Long-Term Outcomes and Preserved Future Treatment Options Randomized Disrupt PAD III Study Finds Superior Vessel Preparation Leads to Excellent Long-Term Outcomes and Preserved Future Treatment Options

Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years

Findings Hold Promise for Female Patients with Calcified Coronary Artery Disease Who Previously Suffered Worse Safety Outcomes than Male Patients Undergoing Atherectomy Findings Hold Promise for Female Patients with Calcified Coronary Artery Disease Who Previously Suffered Worse Safety Outcomes than Male Patients Undergoing Atherectomy

Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men at One Year

The release of Shockwave C² is a similar event to TAVRs for Edwards Lifesciences. Considering the cardiovascular industry tailwinds, the unique niche in calcified stenosis, and safety profile should allow a similar growth trajectory for SWAV.

ShockWave Medical: The Next Edwards

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and expansion in gross margin.

Shockwave Medical (SWAV) Beats on Q1 Earnings & Revenues

ShockWave Medical, Inc. (NASDAQ:SWAV ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Debbie Kaster – Vice President-Investor Relations Doug Godshall – President and Chief Executive Officer Isaac Zacharias – Chief Commercial Officer Dan Puckett – Chief Financial Officer Conference Call Participants Bill Plavonic – Canaccord Adam Maeder – Piper Jaffray Larry Biegelsen – Wells Fargo Daniel Antalffy – SVB Securities Travis Steed – Bank of America Cecilia Furlong – Morgan Stanley Michael Polark – Wolfe Research Operator Good afternoon, and welcome to the ShockWave's First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q1 2022 Results - Earnings Call Transcript

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 105.26% and 5.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Surpasses Q1 Earnings and Revenue Estimates

Shockwave Medical Inc (NASDAQ: SWAV) reported first-quarter revenue of $93.63 million, an increase of 193.5% year-over-year, beating the consensus of $86.41 million. The gross margin for Q1 expanded to 86.2% from 75.3% in 1Q21.

Shockwave Medical Stock Soars On Q1 Earnings Beat, Raised FY22 Guidance

SANTA CLARA, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2022.

Shockwave Medical Reports First Quarter 2022 Financial Results

Aurinia Pharmaceuticals

Outset Medical

Here's why three Fool.com contributors are bullish on Outset Medical, Aurinia Pharmaceuticals, and Shockwave Medical.

3 Healthcare Companies With Revenue Spiking 100% or More

SANTA CLARA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Shockwave Medical Announces Details for Conference Call Discussing First Quarter 2022 Results and Participation in Upcoming Investor Conferences

These two companies are leading the charge for improved patient outcomes.

2 Medtech Stocks You Can Buy and Hold for the Next Decade

Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.

Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time

Shockwave M5+ IVL Catheter Broadens Options for Treatment of Peripheral Arteries Shockwave M5+ IVL Catheter Broadens Options for Treatment of Peripheral Arteries

Shockwave Medical Announces Global Launch of New Peripheral Intravascular Lithotripsy Catheter

Transformative Shockwave C2 Intravascular Lithotripsy Catheter Will Soon Be Available in One of the World's Largest Coronary Intervention Markets

Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shockwave Medical (SWAV) is a Top-Ranked Momentum Stock: Should You Buy?

Pioneer of IVL Selected as the Second Most Innovative Medical Device Company Pioneer of IVL Selected as the Second Most Innovative Medical Device Company

Shockwave Medical Named to Fast Company's "Most Innovative Company" List

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and expansion in gross margin.

Shockwave Medical (SWAV) Gains 3.2% Post Q4 Earnings Beat

Appian

It was a tough day on Wall Street overall.

Look Out for Thursday's 2 Big After-Hours Stock Winners

ShockWave Medical's (SWAV) CEO Doug Godshall on Q4 2021 Results - Earnings Call Transcript

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 385.71% and 11.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Q4 Earnings and Revenues Beat Estimates

SANTA CLARA, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2021.

Shockwave Medical Reports Fourth Quarter and Full Year 2021 Financial Results

SANTA CLARA, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company will be participating in the SVB Leerink 11th Annual Global Healthcare Conference, scheduled to be held virtually from February 14-18, 2022.

Shockwave Medical to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

The opposite of the old adage to "buy the rumor, sell the news" doesn't apply to ShockWave.

Should Investors Sell the Rumor With ShockWave Medical?

Buyout rumors have been swirling around this mid-cap medtech company this week.

Here's Why ShockWave Medical Stock Is Perking Up This Week

Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Shockwave Medical Stock (SWAV)